Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Lonza Appoints Richard Ridinger as New CEO

Published: Thursday, April 05, 2012
Last Updated: Thursday, April 05, 2012
Bookmark and Share
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.

At a meeting on 2 April 2012, the Board of Directors of Lonza elected Mr. Richard Ridinger as the new CEO of Lonza.

Mr. Ridinger will become CEO of Lonza effective 1 May. Rolf Soiron was acting CEO ad interim, since the end of January.

Richard Ridinger is 53 years old, a German national, and has extensive industrial leadership experience. “Richard Ridinger could be a person who grew up with Lonza”, said Rolf Soiron.

Soiron continues, “He is a chemical engineer who knows our industries, customers and products. With Richard Ridinger, we were not only able to attract a man of action and team player, but also a winning personality.”

Richard Ridinger has held numerous leadership functions at Henkel for 14 years and Cognis for 11 years.

Most recently, Mr. Ridinger was responsible for Care Chemicals, the largest sector at Cognis with approximately 3,000 employees.

During his tenure, sales increased by 60% to €1.75 billion over six years, as he successfully repositioned the business in the market.

Mr. Ridinger’s experience spans process development, production management, product- and marketing management of different product areas, leading global business units and finally the co-responsibility for leading a worldwide group of the specialty chemicals.

In working together with the private equity owners of Cognis, Richard Ridinger has proven his ability to achieve business excellence as well as to fulfill strategic and economical goals.

Following the takeover of Cognis by BASF at end of 2010, Richard Ridinger supported the integration of the company.

As CEO of Lonza, Mr. Ridinger has been mandated with strengthening Lonza’s market position in relevant markets, strengthening competitive capabilities, and productivity improvement in critical areas.

Productivity improvement includes project “Visp Challenge”, which is expected to contribute more than CHF 100 million over three years, and it also includes a review of group-wide structures.

The goal of these measures is a stepwise improvement of growth and return on capital.

At the 2 April meeting, the Board of Directors also appointed Mr. Marc Funk, Group General Counsel and Board Secretary, to become a member of the Management Committee.

Marc Funk joined Lonza in January 2009; prior he was associate general counsel at Merck Serono.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lonza and Benitec Enter Agreement
Agreement to develop scalable AAV manufacturing process for ddRNAi therapeutics.
Friday, October 09, 2015
Lonza and CytoMate Collaboration on CytoSMART™ Technology
Agreement for global distribution of the new technology which is designed for easy, affordable live cell imaging.
Thursday, March 05, 2015
Lonza and arGEN-X Announces Commercial License Agreement
A multi-product GS Xceed™ license agreement for the production of therapeutic antibodies.
Friday, February 20, 2015
Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza to Expand ADC Manufacturing Capacity
Capacity expansion is expected to be complete in the second quarter of 2014.
Thursday, January 10, 2013
Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.
Thursday, April 19, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.
Friday, May 18, 2007
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Michigan Researchers Use Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos